

**General information about company**

Name of The Company	BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED
BSE Scrip Code	524396
NSE Symbol	BIOFILCHEM
MSE Symbol	NOTLISTED
Date of Start of Financial Year	01-04-2021
Date of End of Financial Year	31-03-2022
Reporting Period	First half yearly
Date of Start of Reporting Period	01-04-2021
Date of End of Reporting Period	30-09-2021
Level of rounding used in financial results	Lakhs
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

**Related party transactions**

		Sr	1	2	3	4	5	
<b>A. Details of related party</b>	Name of the related party		CYANO PHARMA PRIVATE LIMITED	FORMO PLAST PRIVATE LIMITED	KETAN SHAH	MEET SHAH	SHIKHA KHILWANI	J
	Categories of related parties		Other related party	Other related party	Promoters Group	Promoters Group	Key management personnel of entity or parent	m p
	description of relationship		Director are members in the Company and relative of director are directors & Members in the company	Directors and their relatives are directors and Members in the Company	Persons belongs to promoter group and Whole Time Director (KMP) of the Company	Persons belongs to promoter group	Company Secretary & Compliance Officer of the Company	O
	PAN of related party		AACCC2242F	AAACF2974P	AHCPS6094F	CNCPS6749B	BXGPK2963J	BU
	CIN of related party		U24232MH2000PTC283629	U02520MP1990PTC005863				
<b>B. Details of related party transactions</b>	Purchase of goods and services		7.41394					
	Sale of goods and services		662.40056					
	Purchase of fixed assets							
	Sale of fixed assets							
	Rendering of services							
	Receiving of services		49.796					
	Leases							
	Loans and advances given							
	Loans and advances taken							
	Loans and advances given that are repaid							
	Loans and advances taken that are repaid							
	Deposits placed							
	Deposits taken							
	Transfer of research & development							
	Transfers under lease agreement							
	Equity investment							
	Impairment in equity investment							
	Expense for bad or doubtful debts							
Guarantees								

		or collateral given						
		Guarantees or collateral taken						
		Interest income						
		Interest paid		1.93434				
		Dividend income						
		Dividend paid						
		Management contracts including for deputation of employees						
		Settlement of liabilities by entity on behalf of related party						
	<b>Remuneration</b>	Short term employee benefits			8.7	1.8	2.34	
		Post employment benefits						
Other long-term benefits								
Termination benefits								
Share based payments								
	Others							
<b>C. Outstanding balances</b>	<b>Receivables</b>	Secured						
		Un Secured	1039.91858					
	<b>Payables</b>	Secured						
		Un Secured			1.03192	0.26233	0.38792	
	<b>Loans and advances</b>	Secured						
		Un Secured						
	<b>Loans and advances given</b>	Secured						
		Un Secured		44.72574				
	<b>Deposits placed</b>	Secured						
		Un Secured						
	<b>Deposits taken</b>	Secured						
		Un Secured						
	<b>Guarantees or collateral given</b>	Secured						
		Un Secured						
	<b>Guarantees or collateral taken</b>	Secured						
		Un Secured						
	<b>Investment in equity</b>	Secured						
		Un Secured						
	<b>Provision for doubtful debt</b>	Secured						
		Un Secured						
<b>Note</b>		Sales: Rs. 6,62,40,056 Purchase: Rs. 7,41,394 Jobwork: Rs. 49,79,600  Outstanding Receivables: Rs. 10,39,91,858	Interest on Borrowings: Rs. 1,93,434  Outstanding Loan Payable: Rs. 44,72,574	Salary: Rs. 8,70,000 Outstanding Salary Payable: Rs. 1,03,192	Salary: Rs. 1,80,000 Outstanding Salary Payable: Rs. 26,233	Salary: Rs. 2,34,000 Outstanding Salary Payable: Rs. 38,792	S C P	

